Terms: = Prostate cancer AND ERG, P11308, 2078
1228 results:
1. Transcription Factors in prostate cancer: Insights for Disease Development and Diagnostic and Therapeutic Approaches.
Silva KCS; Tambwe N; Mahfouz DH; Wium M; Cacciatore S; Paccez JD; Zerbini LF
Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674385
[TBL] [Abstract] [Full Text] [Related]
2. Ductal Adenocarcinoma of the prostate with Novel Genetic Alterations Characterized by Next-Generation Sequencing.
Zara Rozalen A; Martin JM; Rajendran R; Jain M; Nava VE
Curr Oncol; 2024 Mar; 31(3):1556-1561. PubMed ID: 38534951
[TBL] [Abstract] [Full Text] [Related]
3. Amplification of different satellite-DNAs in prostate cancer.
Ariffen NA; Ornellas AA; Alves G; Shana'ah AM; Sharma S; Kankel S; Jamali E; Theis B; Liehr T
Pathol Res Pract; 2024 Apr; 256():155269. PubMed ID: 38522124
[TBL] [Abstract] [Full Text] [Related]
4. TP63-TRIM29 axis regulates enhancer methylation and chromosomal instability in prostate cancer.
Sultanov R; Mulyukina A; Zubkova O; Fedoseeva A; Bogomazova A; Klimina K; Larin A; Zatsepin T; Prikazchikova T; Lukina M; Bogomiakova M; Sharova E; Generozov E; Lagarkova M; Arapidi G
Epigenetics Chromatin; 2024 Mar; 17(1):6. PubMed ID: 38481282
[TBL] [Abstract] [Full Text] [Related]
5. Brain metastasis in a patient with BRCA2-mutated treatment-related neuroendocrine prostate carcinoma and long-term response to radiotherapy and Olaparib: A case report and literature review.
Uehara R; Obinata D; Hashimoto S; Nakahara K; Uchida H; Yoshizawa T; Mochida J; Yamaguchi K; Sakaguchi M; Ozawa Y; Mori F; Miura K; Ishige T; Masuda S; Nakayama T; Takahashi S
Medicine (Baltimore); 2024 Mar; 103(9):e37371. PubMed ID: 38428891
[TBL] [Abstract] [Full Text] [Related]
6. Identification of recurrent BRAF non-V600 mutations in intraductal carcinoma of the prostate in Chinese populations.
Hu J; Chen X; Sun F; Liu L; Liu L; Yang Z; Zhang H; Yu Z; Zhao R; Wang Y; Liu H; Yang X; Sun F; Han B
Neoplasia; 2024 Apr; 50():100983. PubMed ID: 38417222
[TBL] [Abstract] [Full Text] [Related]
7. Molecular complexity of intraductal carcinoma of the prostate.
Zhu S; Xu N; Zeng H
Cancer Med; 2024 Jan; 13(2):e6939. PubMed ID: 38379333
[TBL] [Abstract] [Full Text] [Related]
8. Individualized detection of TMPRSS2-erg fusion status in prostate cancer: a rank-based qualitative transcriptome signature.
Li Y; Su H; Liu K; Zhao Z; Wang Y; Chen B; Xia J; Yuan H; Huang DS; Gu Y
World J Surg Oncol; 2024 Feb; 22(1):49. PubMed ID: 38331878
[TBL] [Abstract] [Full Text] [Related]
9. Repeated prostate cancer Screening Using prostate-Specific Antigen Testing and Magnetic Resonance Imaging: A Secondary Analysis of the STHLM3-MRI Randomized Clinical Trial.
Nordström T; Annerstedt M; Glaessgen A; Carlsson S; Clements M; Abbadi A; Grönberg H; Jäderling F; Eklund M; Discacciati A
JAMA Netw Open; 2024 Feb; 7(2):e2354577. PubMed ID: 38324313
[TBL] [Abstract] [Full Text] [Related]
10. Semi-Supervised, Attention-Based Deep Learning for Predicting TMPRSS2:erg Fusion Status in prostate cancer Using Whole Slide Images.
Omar M; Xu Z; Rand SB; Alexanderani MK; Salles DC; Valencia I; Schaeffer EM; Robinson BD; Lotan TL; Loda M; Marchionni L
Mol Cancer Res; 2024 Apr; 22(4):347-359. PubMed ID: 38284821
[TBL] [Abstract] [Full Text] [Related]
11. PTEN, erg, SPINK1, and TFF3 Status and Relationship in a prostate cancer Cohort from Jordanian Arab Population.
Al Bashir S; Alorjani MS; Kheirallah K; Al Hamad M; Haddad HK; Al-Dwairy A; Bani-Fawwaz BA; Aldaoud N; Halalsheh O; Amawi S; Matalka II
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256434
[No Abstract] [Full Text] [Related]
12. Aggressive prostatic adenocarcinoma with urothelial-like morphology, with frequent CK7/CK20/HMWK expression and occasional diffuse neuroendocrine features: A clinicopathologic study of 12 cases.
Nguyen NJ; Sherman C; van der Kwast TH; Downes MR
Pathol Res Pract; 2024 Feb; 254():155105. PubMed ID: 38218041
[TBL] [Abstract] [Full Text] [Related]
13. cAMP-phosphodiesterase 4D7 (PDE4D7) forms a cAMP signalosome complex with DHX9 and is implicated in prostate cancer progression.
Gulliver C; Busiau T; Byrne A; Findlay JE; Hoffmann R; Baillie GS
Mol Oncol; 2024 Mar; 18(3):707-725. PubMed ID: 38126155
[TBL] [Abstract] [Full Text] [Related]
14. FASN Gene Methylation is Associated with Fatty Acid Synthase Expression and Clinical-genomic Features of prostate cancer.
Dairo O; DePaula Oliveira L; Schaffer E; Vidotto T; Mendes AA; Lu J; Huynh SV; Hicks J; Sowalsky AG; De Marzo AM; Joshu CE; Hanratty B; Sfanos KS; Isaacs WB; Haffner MC; Lotan TL
Cancer Res Commun; 2024 Jan; 4(1):152-163. PubMed ID: 38112617
[TBL] [Abstract] [Full Text] [Related]
15. SND1 binds to erg and promotes tumor growth in genetic mouse models of prostate cancer.
Liao SY; Rudoy D; Frank SB; Phan LT; Klezovitch O; Kwan J; Coleman I; Haffner MC; Li D; Nelson PS; Emili A; Vasioukhin V
Nat Commun; 2023 Nov; 14(1):7435. PubMed ID: 37973913
[TBL] [Abstract] [Full Text] [Related]
16. A complex with poly(A)-binding protein and EWS facilitates the transcriptional function of oncogenic ETS transcription factors in prostate cells.
Greulich BM; Rajendran S; Downing NF; Nicholas TR; Hollenhorst PC
J Biol Chem; 2023 Dec; 299(12):105453. PubMed ID: 37956771
[TBL] [Abstract] [Full Text] [Related]
17. Acquired copy number variation in prostate tumours: a review of common somatic copy number alterations, how they are formed and their clinical utility.
O'Malley DE; Raspin K; Melton PE; Burdon KP; Dickinson JL; FitzGerald LM
Br J Cancer; 2024 Feb; 130(3):347-357. PubMed ID: 37945750
[TBL] [Abstract] [Full Text] [Related]
18. Loss of feedback regulation between FAM3B and androgen receptor driving prostate cancer progression.
Ma T; Jin L; Bai S; Liu Z; Wang S; Shen B; Cho Y; Cao S; Sun MJS; Fazli L; Zhang D; Wedderburn C; Zhang DY; Mugon G; Ungerleider N; Baddoo M; Zhang K; Schiavone LH; Burkhardt BR; Fan J; You Z; Flemington EK; Dong X; Dong Y
J Natl Cancer Inst; 2024 Mar; 116(3):421-433. PubMed ID: 37847647
[TBL] [Abstract] [Full Text] [Related]
19. Evaluation of HNF1B, KLK3, ELAC2, TMPRSS2-erg, and CTNNB1 polymorphisms associated with prostate cancer in samples of patients from HUPE-UERJ.
Menezes RDS; Dornas MC; Campos CFF; Rodeiro DB; Carrerette FB; Oliveira RV; de Souza BA; Alves de Souza Carvalho G; Brito IAA; Silva DA; Damião R; Porto LC
Prostate; 2024 Feb; 84(2):166-176. PubMed ID: 37839045
[TBL] [Abstract] [Full Text] [Related]
20. Metastatic prostate cancer is associated with distinct higher frequency of genetic mutations at diagnosis.
Al-Toubat M; Serrano S; Elshafei A; Koul K; Feibus AH; Balaji KC
Urol Oncol; 2023 Nov; 41(11):455.e7-455.e15. PubMed ID: 37838503
[TBL] [Abstract] [Full Text] [Related]
[Next]
